A Risk-Benefit Assessment of Natural and Synthetic Exogenous Surfactants in the Management of Neonatal Respiratory Distress Syndrome

Author： Walti H. Monset-Couchard M.

Publisher： Adis International

ISSN： 0114-5916

Source： Drug Safety, Vol.18, Iss.5, 1998-05, pp. : 321-337

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lung Surfactants for Neonatal Respiratory Distress Syndrome: Animal-Derived or Synthetic Agents?

By Suresh G.K. Soll R.F.

Pediatric Drugs, Vol. 4, Iss. 8, 2002-01 ,pp. : 485-492

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Therapies for Lennox-Gastaut Syndrome

By Schmidt D.

Drug Safety, Vol. 22, Iss. 6, 2000-06 ,pp. : 467-477

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Drugs Used for Neonatal Chronic Lung Disease

By Sweet D.G. Halliday H.L.

Drug Safety, Vol. 22, Iss. 5, 2000-05 ,pp. : 389-404

Adis International

Access to resources Recommend Favorite

A Risk-Benefit Assessment of Epoetin in the Management of Anaemia Associated with Cancer

By Beguin Y.

Drug Safety, Vol. 19, Iss. 4, 1998-10 ,pp. : 269-282

Adis International

Access to resources Recommend Favorite